These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 30307529)
1. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ciavarella S; Vegliante MC; Fabbri M; De Summa S; Melle F; Motta G; De Iuliis V; Opinto G; Enjuanes A; Rega S; Gulino A; Agostinelli C; Scattone A; Tommasi S; Mangia A; Mele F; Simone G; Zito AF; Ingravallo G; Vitolo U; Chiappella A; Tarella C; Gianni AM; Rambaldi A; Zinzani PL; Casadei B; Derenzini E; Loseto G; Pileri A; Tabanelli V; Fiori S; Rivas-Delgado A; López-Guillermo A; Venesio T; Sapino A; Campo E; Tripodo C; Guarini A; Pileri SA Ann Oncol; 2018 Dec; 29(12):2363-2370. PubMed ID: 30307529 [TBL] [Abstract][Full Text] [Related]
2. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724 [TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. Scott DW; Mottok A; Ennishi D; Wright GW; Farinha P; Ben-Neriah S; Kridel R; Barry GS; Hother C; Abrisqueta P; Boyle M; Meissner B; Telenius A; Savage KJ; Sehn LH; Slack GW; Steidl C; Staudt LM; Connors JM; Rimsza LM; Gascoyne RD J Clin Oncol; 2015 Sep; 33(26):2848-56. PubMed ID: 26240231 [TBL] [Abstract][Full Text] [Related]
4. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Alizadeh AA; Gentles AJ; Alencar AJ; Liu CL; Kohrt HE; Houot R; Goldstein MJ; Zhao S; Natkunam Y; Advani RH; Gascoyne RD; Briones J; Tibshirani RJ; Myklebust JH; Plevritis SK; Lossos IS; Levy R Blood; 2011 Aug; 118(5):1350-8. PubMed ID: 21670469 [TBL] [Abstract][Full Text] [Related]
5. Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling. Mosquera Orgueira A; Díaz Arias JÁ; Cid López M; Peleteiro Raíndo A; Antelo Rodríguez B; Aliste Santos C; Alonso Vence N; Bendaña López Á; Abuín Blanco A; Bao Pérez L; González Pérez MS; Pérez Encinas MM; Fraga Rodríguez MF; Bello López JL BMC Cancer; 2020 Oct; 20(1):1017. PubMed ID: 33087075 [TBL] [Abstract][Full Text] [Related]
6. Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor score. Tekin N; Omidvar N; Morris TP; Conget P; Bruna F; Timar B; Gagyi E; Basak R; Naik O; Auewarakul C; Sritana N; Levy D; Cerci JJ; Bydlowski SP; Pereira J; Dimamay MP; Natividad F; Chung JK; Belder N; Kuzu I; Paez D; Dondi M; Carr R; Ozdag H; Padua RA Oncotarget; 2016 Dec; 7(50):83319-83329. PubMed ID: 27825111 [TBL] [Abstract][Full Text] [Related]
7. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y Front Immunol; 2022; 13():950213. PubMed ID: 36072582 [TBL] [Abstract][Full Text] [Related]
8. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046 [TBL] [Abstract][Full Text] [Related]
9. An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment. Liang XJ; Fu RY; Wang HN; Yang J; Yao N; Liu XD; Wang L J Immunol Res; 2021; 2021():5564568. PubMed ID: 34212052 [TBL] [Abstract][Full Text] [Related]
10. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Rimsza LM; Wright G; Schwartz M; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Cook JR; Tubbs RR; Braziel RM; Delabie J; Miller TP; Staudt LM Clin Cancer Res; 2011 Jun; 17(11):3727-32. PubMed ID: 21364035 [TBL] [Abstract][Full Text] [Related]
11. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G; J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305 [TBL] [Abstract][Full Text] [Related]
12. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544 [TBL] [Abstract][Full Text] [Related]
13. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index. Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453 [TBL] [Abstract][Full Text] [Related]
16. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces. Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480 [TBL] [Abstract][Full Text] [Related]
17. High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified. Hwang HS; Park CS; Yoon DH; Suh C; Huh J Am J Surg Pathol; 2014 Aug; 38(8):1046-57. PubMed ID: 24705314 [TBL] [Abstract][Full Text] [Related]
18. Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent. Risueño A; Hagner PR; Towfic F; Fontanillo C; Djebbari A; Parker JS; Drew CP; Nowakowski GS; Maurer MJ; Cerhan JR; Wei X; Ren Y; Lee CW; Couto S; Wang M; Pourdehnad M; Gandhi AK; Trotter MWB Blood; 2020 Mar; 135(13):1008-1018. PubMed ID: 31977005 [TBL] [Abstract][Full Text] [Related]
19. Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma. Wang J; Wang Y; Wan L; Chen X; Zhang H; Yang S; Zhong L Front Immunol; 2023; 14():1230017. PubMed ID: 37790933 [TBL] [Abstract][Full Text] [Related]
20. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes. Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S J BUON; 2015; 20(3):820-8. PubMed ID: 26214636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]